Question 1

What is tirzepatide, and what is known about its use?

Accepted Answer

Tirzepatide is a GIP and GLP-1 receptor agonist studied for glycemic control in type 2 diabetes and chronic weight management in specific groups. It affects metabolic signals related to glucose, satiety, and gastric emptying. The appropriate indication depends on the authorized product, country, diagnosis, and clinical assessment; this calculator does not confirm authenticity or suitability. Large randomized trials, including SURPASS and SURMOUNT, report metabolic benefits in the populations studied. Nausea, diarrhea, vomiting, and constipation are common, particularly during treatment changes. Group averages cannot predict an individual's response or justify transferring concentrations between presentations. No supplement has been proven to increase efficacy or make treatment safe. Hydration, adequate nutrition, and correction of a professionally identified deficiency may be part of general care, but self-selected supplements can worsen gastrointestinal symptoms or conflict with other conditions and medicines. There is no universal “best time.” Products and indications have their own instructions, and timing should follow the valid label and prescriber's guidance. Do not change intervals, presentations, or concentrations based on online content. Discuss gastrointestinal, pancreatic, gallbladder, kidney, pregnancy, diabetes, and glucose-lowering medication history with a clinician. Seek care for severe or persistent symptoms. This summary does not recommend starting, stopping, or adjusting treatment. This content is for information only. It is not medical advice, a prescription, a dose recommendation, or an administration instruction.

Question 2

What is retatrutide, and what is the current evidence level?

Accepted Answer

Retatrutide (LY3437943) is an experimental triple agonist of GIP, GLP-1, and glucagon receptors under investigation for obesity, type 2 diabetes, and related metabolic conditions. Clinical development is ongoing; research findings do not equal broad authorization or validate products sold outside controlled studies. Phase 1 and 2 studies reported changes in body weight and glycemic markers in studied populations, with gastrointestinal events and heart-rate changes among monitored safety findings. The breadth of data, follow-up, and post-marketing surveillance available for established therapies is not yet present. No supplement combination has been validated to improve outcomes or prevent retatrutide adverse effects. Nutritional deficiencies should be assessed and treated individually; online “stacks” add uncertainty and risk without reliable clinical evidence. There is no established administration time for routine use outside research protocols. Frequencies used in trials belong to those study designs and should not be converted into personal instructions. The quality, sterility, and concentration of unregulated products cannot be inferred from a label. Any exposure should be discussed with a clinician; important symptoms require assessment, and this calculator only converts entered values. This content is for information only. It is not medical advice, a prescription, a dose recommendation, or an administration instruction.

Question 3

What is semaglutide, and which uses have been studied?

Accepted Answer

Semaglutide is a GLP-1 receptor agonist studied and used, depending on product and jurisdiction, for type 2 diabetes, chronic weight management, and cardiovascular risk reduction in defined populations. Injectable and oral presentations have different instructions; concentration, frequency, and administration details are not interchangeable. SUSTAIN, PIONEER, STEP, and SELECT provide extensive human evidence for glycemic, weight, and—in defined groups—cardiovascular outcomes. Gastrointestinal effects are common. Benefits and risks depend on indication, comorbidities, and other medicines, so population evidence does not replace individual assessment. No supplement is needed to “activate” semaglutide or has been proven to prevent adverse effects. Hydration and adequate nutrition are general care; vitamins, minerals, or protein supplements should address an assessed dietary need or deficiency, not a generic protocol. There is no single best time for every presentation. Oral formulations have specific requirements, and injectables follow the label for the exact product. Use only official instructions and professional guidance for the actual presentation. Tell a clinician about other diabetes medicines and gastrointestinal, pancreatic, gallbladder, kidney, eye, pregnancy, or planned-surgery history. Severe or persistent symptoms should not be managed with an online calculator alone. This content is for information only. It is not medical advice, a prescription, a dose recommendation, or an administration instruction.

Question 4

What is BPC-157, and is there scientific evidence in humans?

Accepted Answer

BPC-157 is a synthetic peptide promoted in tendon, muscle, and gastrointestinal repair contexts. These claims mainly come from animal and laboratory models. Such studies do not establish clinical efficacy, long-term safety, or an appropriate human administration method. Published literature is dominated by rat studies, often from a limited number of research groups. A recent pilot involved only two previously exposed people and cannot establish efficacy or general safety. There is no robust clinical basis for recovery, performance, or gastrointestinal protocols. No supplement has been proven to complement or protect during BPC-157 use. Protein, micronutrients, and rehabilitation may matter for health and recovery when indicated, but they do not validate the peptide or offset uncertainties about sterility, identity, and concentration. There is no best time supported by human clinical trials and no approved schedule that can safely be reproduced from animal studies. Tendon, muscle, and digestive symptoms need diagnosis; masking pain can delay proper care. Research products may not match their labels. This content is informational and does not instruct use. This content is for information only. It is not medical advice, a prescription, a dose recommendation, or an administration instruction.

Question 5

What is TB-500, and how does it relate to thymosin beta-4?

Accepted Answer

TB-500 is a name used for products associated with synthetic fragments of thymosin beta-4 (Tβ4), a protein involved in actin dynamics and cellular repair. Commercial TB-500 and full-length Tβ4 should not automatically be treated as the same substance; many studies cited in promotion concern Tβ4, not a product labeled TB-500. There is preclinical research on cardiac and corneal repair and small human studies of topical Tβ4 formulations for eyes or wounds. This does not prove benefit, safety, or equivalence of injectable TB-500 for sports injuries or systemic recovery. No supplement or combination has been validated for TB-500. Rehabilitation, sleep, and nutrition may be part of clinician-guided injury care, but they do not replace diagnosis or make an experimental product safe. There is no evidence-based administration time or schedule for TB-500. Protocols found in forums are not equivalent to studied recommendations. Distinguishing molecules, formulations, and routes is essential when reading studies. Injuries, wounds, and eye symptoms deserve professional assessment; uncontrolled products may be contaminated or mislabeled. This content is for information only. It is not medical advice, a prescription, a dose recommendation, or an administration instruction.

Question 6

What is GHK-Cu, and which uses have scientific support?

Accepted Answer

GHK-Cu is a naturally occurring copper-binding tripeptide. It is studied in relation to extracellular matrix, fibroblasts, and tissue repair, especially in skin and wound models. Topical cosmetic applications and injectable products are different contexts and do not automatically share the same evidence. Cell and animal studies report effects on collagen and wound healing; ex-vivo human-skin work helps characterize topical penetration. Clinical evidence for cosmetic benefit is limited and heterogeneous, and available research does not establish the safety or benefit of systemic injection. There is no proven reason to combine oral copper or other supplements with GHK-Cu. Excess copper can be harmful; supplementation should occur only after clinical assessment of diet, tests, and individual conditions. There is no universal best time. For regulated cosmetics, follow the label and dermatologic guidance; that must not be converted into an instruction for injectable formulations. Irritation, allergy, formulation quality, and interaction with other skin products matter. Claims about hair, systemic rejuvenation, or recovery should be separated from what was actually tested. This content is for information only. It is not medical advice, a prescription, a dose recommendation, or an administration instruction.

Question 7

What is CJC-1295, and what do studies actually show?

Accepted Answer

CJC-1295 is a long-acting growth-hormone-releasing hormone (GHRH) analog developed to prolong GH/IGF-1 axis signaling. Products also use similar names, including versions described as “without DAC,” and should not be assumed equivalent to the compound studied. Small studies in healthy adults showed sustained increases in GH and IGF-1 and preserved pulsatility, but did not demonstrate long-term clinical benefits for body composition, recovery, sleep, or aging. Some listed references concern the broader GHRH class rather than CJC-1295 directly. No supplement has been proven to make GH/IGF-1 modulation safer. Combining secretagogues increases uncertainty and cannot be justified by studies of each substance in isolation. There is no validated best time for routine clinical CJC-1295 use. Pharmacologic duration is not an administration schedule. Changes in the GH/IGF-1 axis can have metabolic, fluid-retention, and other individual risks. Product identity and differences between variants are major limitations. This content is for information only. It is not medical advice, a prescription, a dose recommendation, or an administration instruction.

Question 8

What is ipamorelin, and what clinical results are available?

Accepted Answer

Ipamorelin is a GH secretagogue peptide and ghrelin-receptor agonist. It has been studied in human pharmacology and as a possible treatment for postoperative ileus. Interest in body composition, sleep, or recovery extends beyond the main objectives of published clinical evidence. A volunteer study characterized GH response and pharmacokinetics. A phase 2 trial after bowel surgery found no statistically significant difference in its main food-tolerance endpoint; other relevant findings are preclinical. This does not support general performance or anti-aging protocols. No supplement stack has been proven to increase benefit or reduce risk. Combining ipamorelin with GHRH analogs or other hormones changes the biology and cannot be justified by monotherapy results. There is no evidence-based best time for promoted uses outside research. Hormone peaks observed in a laboratory do not amount to an administration recommendation. Effects on glucose, appetite, fluid retention, and hormonal signaling require caution, in addition to quality risks of unregulated products. This summary does not instruct starting or combining substances. This content is for information only. It is not medical advice, a prescription, a dose recommendation, or an administration instruction.

Question 9

What is tesamorelin, and where is there clinical evidence?

Accepted Answer

Tesamorelin is a stabilized GHRH analog that stimulates endogenous GH and IGF-1 production. It has primarily been studied for reducing excess abdominal visceral fat in people with HIV and lipodystrophy, a specific clinical setting that should not be generalized to weight loss, performance, or aging. Randomized trials and extensions reported visceral-fat reductions in the studied population; research has also examined liver fat in people with HIV. Effects may reverse after discontinuation, and glucose, IGF-1, local reactions, and other safety issues require monitoring. No supplement is required or proven to enhance tesamorelin. Nutrition and correction of deficiencies are part of overall care when indicated, but do not replace clinical monitoring or broaden the studied indication. Timing and frequency belong to the authorized product label and prescriber's plan. This site cannot recommend a universal best time. Assessment should consider glucose, IGF-1, cancer history, pregnancy, pituitary status, and concomitant medicines. HIV studies do not validate uncertain-source products or use for other goals. This content is for information only. It is not medical advice, a prescription, a dose recommendation, or an administration instruction.

Question 10

Does the calculator tell me what dose to use?

Accepted Answer

No. You always enter the dose to calculate. The tool only converts that value mathematically.

Question 11

What does U-100 mean?

Accepted Answer

In this calculator, U-100 is a scale with 100 units per mL. Therefore, 0.125 mL mathematically corresponds to 12.5 units.

Question 12

Are my values stored?

Accepted Answer

No. Substance, dose, concentration, and result stay in your browser and are not sent to a server.

Question 13

Can I use the concentration from another presentation of the same brand?

Accepted Answer

Do not assume presentations from the same brand are identical. Always check total mg and volume in mL on the specific packaging.

Concentration calculator

Mathematical conversion only

Two formulas, one transparent result

1. Volume in mL

2. U-100 units

Visible precision

The essentials, in plain language

Overview and studied uses

What the evidence shows

Supplements and supportive care

Timing of use

Relevant considerations

Articles and studies for further reading

Overview and studied uses

What the evidence shows

Supplements and supportive care

Timing of use

Relevant considerations

Articles and studies for further reading

Overview and studied uses

What the evidence shows

Supplements and supportive care

Timing of use

Relevant considerations

Articles and studies for further reading

Overview and studied uses

What the evidence shows

Supplements and supportive care

Timing of use

Relevant considerations

Articles and studies for further reading

Overview and studied uses

What the evidence shows

Supplements and supportive care

Timing of use

Relevant considerations

Articles and studies for further reading

Overview and studied uses

What the evidence shows

Supplements and supportive care

Timing of use

Relevant considerations

Articles and studies for further reading

Overview and studied uses

What the evidence shows

Supplements and supportive care

Timing of use

Relevant considerations

Articles and studies for further reading

Overview and studied uses

What the evidence shows

Supplements and supportive care

Timing of use

Relevant considerations

Articles and studies for further reading

Overview and studied uses

What the evidence shows

Supplements and supportive care

Timing of use

Relevant considerations

Articles and studies for further reading